Ambiguous genitalia in infant exposed to tamoxifen in utero [1]

Lancet

Volumn 350, Issue 9072, 1997, Pages 183-

  Tewari, Krishnansu ^b   Bonebrake, Robert G ^b   Asrat, Tamerou ^a   Shanberg, Allan M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; FEMALE; FEMALE GENITAL TRACT MALFORMATION; HUMAN; LETTER; PRENATAL EXPOSURE; PRIORITY JOURNAL;

EID: 0342460593     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)24029-8     Document Type: Article

References (5)

1. Tucker MJ, Adam HK, Patterson JS. Tamoxifen. In: Laurence DR McLean AEM, Wetherall M, eds. Safety testing of new drugs: laboratory predictions and clinical performance. London: Academic Press, 1984: 125-61.
2. Chamness GC, Bannayan LA, Landry JR, et al. Abnormal reproductive development in rats after neonatally administered antiestrogen (tamoxifen). Biol Reprod 1979; 21: 1087-90.
3. Iguchi T, Hirokawa M, Takasugi M. Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology 1986; 42: 1-11.
4. Cunha GR, Taguchi O, Namikawa R, Nishizuka Y, Robboy SJ. Teratogenic effects of clomiphene, tamoxifen and diethylstilbestrol on the developing human female genital tract. Hum Pathol 1987; 18: 1132-43.
5. Clark S. Prophylactic tamoxifen. Lancet 1993; 342: 168.